

The Evolution of a Beta-Lactam Resistance: A holistic narrative

Mineli Cooray¹, Tom Ashfield², Isabel Jimenez Acha³, Mato Lagator³



¹University of Warwick, ²Pfizer Ltd., ³University of Manchester

Introduction

Antimicrobial resistance (AMR) is a major humanitarian and global threat.¹ Antimicrobials deliver extensive value in reducing global burden of infection² and in enabling healthcare.³ As the centenary of Fleming's discovery approaches,⁴ we must focus holistically to learn from history. We therefore approached this with a narrative exploration of beta-lactam development and policy through the lens of resistance evolution. The study of resistance evolution focuses on proximate causes under controlled conditions. Conversely, the association between resistance evolution and policy is poorly understood.

A focus on beta-lactam antibiotics was taken, given their clear development timeline and continuous molecular refinement to meet arising clinical and microbiological needs.

Objectives

- Undertake an ontological appraisal of beta-lactam development, clinical use and associated resistance;
- Illustrate key timelines in resistance evolution with case study examples;
- Provide a historical basis for future projected recommendations that can mitigate resistance evolution.

Methods

- A reference timeline of beta-lactam development, initial clinical use and first encounter of resistance was constructed through extensive literature and repository searches. This was illustrated through the use of Miroboard[™] to aid structure and understanding;
- Key events within this timeline were explored in depth with case study examples; the influence of each was explored in terms of subsequent

resistance evolution. The timeline was reviewed to the present day, with the below timeline iterating the most relevant case studies.

Findings



Discussion

- Key events in the resistance evolution timeline have been used to illustrate key learning points from the past
- Knowledge and solutions now exist but global policy lags behind in implementation of an AMS focussed agenda
- There is a strong case for evolutionary microbiology theory to be integrated with policy, industrial decision-making and forecasting for appropriate use and future development
- An AMS focus across all organisational levels and relevant stakeholders is necessary to mitigate the grave threat of AMR.

References

1) Programme UE. Antimicrobial resistance: a global threat United Nations Environment Programme UN Environment Programme2023 [Available from: https://www.unep.org/exploretopics/chemicalswaste/whatwedo/emergingissues/antimicrobialresistanceglobalthreat#:~:text=The%20World%20Health%20Organization%20(WHO,development%2C%20and%20equity%20within%20societies. 2) Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P t. 2015;40(4):277-83. 3) Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Current Opinion in Pharmacology. 2014;18:56-60. 4) The Fleming centre - Keeping antibiotics working for the next 100 years Imperial College Healthcare NHS Trust: Imperial College London; 2023 [cited 2023 Nov]. Available from: https://www.flemingcentre.org/flemingcentre2.htm. 5) Tansey EM, Reynolds LA. POST PENICILLIN ANTIBIOTICS: FROM ACCEPTANCE TO RESISTANCE? A Witness Seminar held at the Wellcome Institute for the History of Medicine, London. ucl.ac.uk; 2000. 6) Bhidé A, Datar S, Stebbins K. Case Histories of Significant Medical Advances: Cephalosporins. Harvard Business School; 2020 7) Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. The Lancet. 2001;357(9271):1851-3. 8) Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6):315-7. 9) Karam GH, Heffner JE. Emerging issues in antibiotic resistance in blood-borne infections. American journal of respiratory and critical care medicine. 2000;162(5):1610-6. 10) Sabath LD, Abraham EP. Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem J. 1966;98(1):11c-3c. 11) Concha NO, Rasmussen BA, Bush K, Herzberg O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure. 1996;4(7):823-36. 12) Matsuura M, Nakazawa H, Hashimoto T, Mitsuhashi S. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains. Antimicrob Agents Chemother. 1980;17(6):908-11. 13) Brown AG. Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development. Drug Des Deliv. 1986;1(1):1-21. 14) Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine M-H. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. Journal of Antimicrobial Chemotherapy. 2002;49(2):367-71. 15) Fluit AC, Jones ME, Schmitz F-J, Acar J, Gupta R, Verhoef J, et al. Antimicrobial Susceptibility and Frequency of Occurrence of Clinical Blood Isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clinical Infectious Diseases. 2000;30(3):454-60. 16) Smith RD, Coast J. Antimicrobial resistance: a global response. Bulletin of the World Health Organization. 2002;80:126-33. 17) Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. Jama. 1998;280(14):1233-7. 18) Gross AE, Johannes RS, Gupta V, Tabak YP, Srinivasan A, Bleasdale SC. The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers. Clin Infect Dis. 2017;65(4):613-8.

	Footnotes			
	a.	National Research and Development Corporation		
	b.	. Extended Spectrum Beta-lactamases		
	c.	Metallo Beta-lactamases		
	d.	d. Antimicrobial Stewardship		
	e.	. Beta-lactam/Beta-lactamase inhibitor combination		
۱ ا	Kau			
	кеу			
	Г			
			Recommendations	
		Key events	based on lessons	
			learnt	